Switch theme
Sign up to access all valuation multiples
Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.
1994
1.5K+
LTM Revenue n/a
LTM EBITDA n/a
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yifan Pharmaceutical has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Yifan Pharmaceutical achieved revenue of $561M and an EBITDA of -$72.0M.
Yifan Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yifan Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $561M | n/a | XXX | XXX | XXX |
| Gross Profit | $252M | $257M | XXX | XXX | XXX |
| Gross Margin | 45% | NaN% | XXX | XXX | XXX |
| EBITDA | -$72.0M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -13% | NaN% | XXX | XXX | XXX |
| Net Profit | $38.4M | $26.4M | XXX | XXX | XXX |
| Net Margin | 7% | NaN% | XXX | XXX | XXX |
| Net Debt | $55.0M | $50.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Yifan Pharmaceutical's stock price is CNY 11 (or $2).
Yifan Pharmaceutical has current market cap of CNY 13.5B (or $1.9B), and EV of CNY 14.9B (or $2.1B).
See Yifan Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $1.9B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Yifan Pharmaceutical has market cap of $1.9B and EV of $2.1B.
Yifan Pharmaceutical's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Yifan Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Yifan Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpYifan Pharmaceutical's NTM/LTM revenue growth is n/a
Yifan Pharmaceutical's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Yifan Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Yifan Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Yifan Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yifan Pharmaceutical acquired XXX companies to date.
Last acquisition by Yifan Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Yifan Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Yifan Pharmaceutical founded? | Yifan Pharmaceutical was founded in 1994. |
| Where is Yifan Pharmaceutical headquartered? | Yifan Pharmaceutical is headquartered in China. |
| How many employees does Yifan Pharmaceutical have? | As of today, Yifan Pharmaceutical has 1.5K+ employees. |
| Is Yifan Pharmaceutical publicy listed? | Yes, Yifan Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Yifan Pharmaceutical? | Yifan Pharmaceutical trades under 002019 ticker. |
| When did Yifan Pharmaceutical go public? | Yifan Pharmaceutical went public in 2004. |
| Who are competitors of Yifan Pharmaceutical? | Similar companies to Yifan Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Yifan Pharmaceutical? | Yifan Pharmaceutical's current market cap is $1.9B |
| Is Yifan Pharmaceutical profitable? | Yes, Yifan Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
